Friday, July 01, 2022 2:28:04 PM
Truth be told, I know nothing about the prospects of this stock to yield a net profit.
Insider selling and their funding principle to attract partners, capturing Lilly and Novartis and others already, with more insider buying from their top execs. tilts to me, a higher probable promise than suppositions I could surmise absent those facts.
The video (I linked) however suggests to me, that DTIL is the most promising scalable medical stock I can think of, even if true its ultimate success will lead to complete unfortunate failure.
The idea that this gene editing platform can conceivably be used to be effective for at least 7K diseases is crucial to proclaim its surpassing promise. The rapid new developments in new computational and experimental methods can avail foreseeing continuous increased effectiveness of this platform, even after periods of enduring inconclusive failure.
Bottom line: I can not recommend as a wise investment the stock DTIL,
But when I match DTIL against all possible investments in charitable enterprises, with the expectations of deriving no profit except tax benefits , I think DTIL is also eligible to receive a "philanthropic" donation, with no prospects of a return, except, to just be able to say, when asked to donate money for some disease, the words "I already gave".
Anyway,if anyone can name a stock with more promising scalable prospects than DTIL, it would to the highest degree, tease my curiosity.
Unfollow Board
Keyboard Sh
Recent DTIL News
- Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024 • Business Wire • 05/01/2024 11:05:00 AM
- Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics • Business Wire • 04/16/2024 08:15:00 PM
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update • Business Wire • 03/27/2024 10:45:00 AM
- Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 • Business Wire • 03/20/2024 08:30:00 PM
- Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy • Business Wire • 03/19/2024 11:00:00 AM
- Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency • Business Wire • 03/06/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:00:25 PM
- Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants • Business Wire • 03/01/2024 11:30:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 03/01/2024 11:00:39 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 10:19:00 PM
- Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants • Business Wire • 02/29/2024 09:01:00 PM
- Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences • Business Wire • 02/20/2024 12:00:00 PM
- Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness • Business Wire • 02/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 01:29:39 PM
- Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations • Business Wire • 02/13/2024 12:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:00:46 PM
- Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases • Business Wire • 02/12/2024 12:00:00 PM
- Precision BioSciences to Effect a Reverse Stock Split • Business Wire • 02/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:19:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:17:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:15:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:13:50 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/24/2024 12:11:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:29:47 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/23/2024 09:27:56 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM